Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ETRAVIRINE

All products: general benefit

Other products in the same Health Canada class (J05A, J05AG) — coverage varies; not interchangeable

  • Delavirdine (Rescriptor): general benefit
  • Doravirine (Pifeltro): general benefit
  • Efavirenz (Sustiva): general benefit, Not a benefit
  • Nevirapine (Viramune XR): general benefit, Not a benefit
  • Rilpivirine (Edurant): general benefit
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit

48 more in the class list below

Intelence · DIN 02306778 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Intelence · DIN 02306778 Manufacturer: Janssen Inc.; listing date 2009-01-30 Health Canada: Marketed since 2008-03-27 · brand INTELENCE · ATC J05AG04 ETRAVIRINE · form Tablet · route Oral · ingredients ETRAVIRINE 100 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Intelence: Formulary list price $6.5710/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.5710 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79246 · Verify on the e-Formulary ↗ (DIN 02306778)

Source record
DIN 02306778: Intelence Raw flags: sec3=Y Item: 081800104; group id 86; item number 0154; lccId None; manufacturer id JAN Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $6.5710; ministry $6.5710 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02306778 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79246
Shortage status: resolved shortage (ended 2024-02-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02306778
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

DELAVIRDINE MESYLATE

· 1 products · General benefit · strengths: 100mg · Tab

DORAVIRINE

· 1 products · General benefit · strengths: 100mg · Tab

EFAVIRENZ

· 5 products · Listed, not a benefit (1), General benefit (4) · strengths: 600mg · Tab

NEVIRAPINE

· 7 products · Listed, not a benefit (2), General benefit (5) · strengths: 400mg, 200mg · ER Tab, Tab

RILPIVIRINE HYDROCHLORIDE

· 1 products · General benefit · strengths: 25mg · Tab

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: human immunodeficiency virus type 1
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, RILPIVIRINE HYDROCHLORIDE DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE · General benefit 1 INDICATIONS SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) is indicated as a complete regimen for: • the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg) and with no known mutations associated with resistance to the individual components of SYMTUZA®. PM: https://pdf.hres.ca/dpd_pm/00069792.PDF; date March 07, 2018; DIN 02473720; fetched 2026-09-10 Product monograph ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE · General benefit 1 INDICATIONS GENVOYA (150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/10 mg tenofovir alafenamide) is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing ≥ 25 kg and with no known mutations associated with resistance to the individual components of GENVOYA. 1.1 Pediatrics Pediatrics (weighing ≥ 25 kg): The safety and efficacy in children weighing ≥ 25 kg are based on data from an open-label clinical study (see 8 ADVERSE REACTIONS and 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00062412.PDF; date November 27, 2015; DIN 02449498; fetched 2026-09-10 Product monograph RILPIVIRINE HYDROCHLORIDE · General benefit 1 INDICATIONS EDURANT® (rilpivirine), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment- naïve adult and pediatric patients 12 years of age and older (and weighing ≥35 kg) with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy. 1.1 Pediatrics Pediatrics (12 to <18 years of age and weighing at least 35 kg): The safety, efficacy and pharmacokinetics of Edurant has been established in antiretroviral treatment-naïve, HIV-1 infected pediatric subjects 12 to less than 18 years of age and weighing at least 35 kg (see 4.2 Recommended Dose and Dosage Adjustment, 10.3 Pharmacokinetics, Pediatrics and 14.1 Clinical Trials by Indication, Treatment-Naïve Pediatric Patients (12 years to less than 18 years of age)). PM: https://pdf.hres.ca/dpd_pm/00077884.PDF; date July 20, 2011; DIN 02370603; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS INTELENCE® (etravirine), in combination with other antiretroviral agents, is indicated for: • the treatment of human immunodeficiency virus type 1 (HIV-1) infection in treatment- experienced adult and pediatric (from 6 to <18 years of age and weighing ≥30 kg) patients who have failed prior therapy and have HIV-1 strains resistant to multiple antiretroviral agents, including NNRTIs (see 4 DOSAGE AND ADMINISTRATION). The adult indication is based on safety and efficacy data at 48 weeks from two Phase III, double- blinded, placebo-controlled trials in treatment-experienced patients who had a least one NNRTI resistance-associated mutation and multiple primary protease inhibitor mutations (see 14 CLINICAL TRIALS for description of studies). 1.1 Pediatrics Pediatrics (<6 years of age) The safety and efficacy of Intelence in pediatric patients <6 years of age have not been established. Treatment with Intelence is not indicated for pediatric patients younger than 6 (see 7 WARNINGS AND PRECAUTIONS and 10.3 Pharmacokinetics) Pediatrics (from 6 to <18 years of age) Intelence, in combination with other antiretroviral agents, is indicated for the treatment of … https://pdf.hres.ca/dpd_pm/00075096.PDF PM date: March 27, 2008 Source product: INTELENCE; DIN 02306778; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.